Condition

Hormone Receptor Positive Malignant Neoplasm of Breast

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 20 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials20

Recruiting3

Common interventions25

Lead sponsors shown15

Clinical trials

20 shown

A Study of Revaree Plus in People With Breast CancerNCT07042581 · 2025-06-20

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283 · 2023-12-01

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyNCT06805812 · 2023-05-01

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNCT06253195 · 2024-04-01

Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.NCT04483505 · 2020-11-25

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast CancerNCT04088110 · 2019-11-01

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast CancerNCT04088032 · 2019-10-01

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast CancerNCT04030507 · 2019-07-26

ACTIVE_NOT_RECRUITING

Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast CancerNCT03969121 · 2019-07-16

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBCNCT03910712 · 2019-06-01

Prospective Thinking in Hormone-Responsive Breast CancerNCT03594578 · 2018-08-01

Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast CancerNCT03088527 · 2017-10-23

Comparison of the Breast Tumor MicroenvironmentNCT03165487 · 2017-09-28

ACTIVE_NOT_RECRUITING

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast CancerNCT02668666 · 2017-02-01

The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian PopulationNCT02347449 · 2014-10-01

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With BevacizumabNCT02248571 · 2014-08-01

Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With ExemestaneNCT02109913 · 2014-03-01

Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast CancerNCT01589367 · 2012-05-01

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence ScoreNCT01617954 · 2012-05-01

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast CancerNCT02025712

Common interventions

Leading sponsors

BeOne Medicines2 Agendia1 Alison Stopeck1 Amsterdam UMC, location VUmc1 Brigham and Women's Hospital1 Columbia University1 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano1 Fundacion CRIS de Investigación para Vencer el Cáncer1 Fuzhou General Hospital1 iOMEDICO AG1 Kyoto Breast Cancer Research Network1 Memorial Sloan Kettering Cancer Center1 Oana Danciu, MD1 Organisation for Oncology and Translational Research1 Peking Union Medical College Hospital1

Trial status mix

COMPLETED10

UNKNOWN4

RECRUITING3

ACTIVE_NOT_RECRUITING2

WITHDRAWN1

Phase mix

PHASE25

NA4

PHASE14

PHASE42

EARLY_PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.